Maynard Um
-
-
-
-
-
-
-
Humacyte (HUMA) PT Lowered to $11 at Benchmark
-
-
-
-
-
-
-
Barclays Starts Humacyte (HUMA) at Overweight
-
-
-
-
-
-
-
Humacyte (HUMA) PT Lowered to $14 at Benchmark
-
-
-
-
-
-
-
Humacyte (HUMA) Announces Pricing of Public Offering of Common Stock
-
-
-
-
-
-
-
Humacyte (HUMA) and Pluristyx Announce Gene Editing Partnership
-
-
-
-
-
-
-
HUMA DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA
-
-
-
-
-
-
-
ROSEN, A RANKED AND LEADING FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

